Trabectedin
Brand names: Evdi · Active ingredient: Trabectedin
In short: EVDI is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen .
What is Trabectedin used for?
EVDI is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen .
Trabectedin dosage
The recommended dose is 1.5 mg/m2 administered as an intravenous infusion over 24 hours through a central venous line every 21 days (3 weeks), until disease progression or unacceptable toxicity.
The recommended dosage of EVDI in patients with moderate hepatic impairment (bilirubin levels greater than 1.5 times to 3 times the upper limit of normal, and AST and ALT less than 8 times the upper limit of normal) is 0.9 mg/m2 every 21 days (3 weeks).
Do not administer EVDI to patients with severe hepatic impairment (bilirubin levels above 3 times the upper limit of normal, and any AST and ALT) .
Administer dexamethasone 20 mg intravenously 30 minutes prior to each dose of EVDI.
Permanently discontinue EVDI for:
Persistent adverse reactions requiring a delay in dosing of more than 3 weeks.
Adverse reactions following the second dosage reduction of EVDI (1.0 mg/m2 for patients with normal hepatic function or at 0.3 mg/m2 for patients with pre-existing moderate hepatic impairment).
Severe liver dysfunction: bilirubin two times the upper limit of normal, and AST or ALT three times the upper limit of normal, and alkaline phosphatase less than two times the upper limit of normal in the prior treatment cycle for patients with normal liver function at baseline.
Exacerbation of liver dysfunction in patients with pre-existing moderate hepatic impairment.
Capillary leak syndrome.
Rhabdomyolysis.
Grade 3 or 4 cardiac adverse events (AEs) indicative of cardiomyopathy or for subjects with an LVEF that decreases below the lower limit of normal.
The recommended dosage modifications for adverse reactions are listed in Table 1. Once reduced, the dose of EVDI should not be increased in subsequent treatment cycles. …
How to take Trabectedin — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Myelosuppression: Inform patients of the risks of myelosuppression. Instruct patients to immediately contact their healthcare provider for fever or unusual bruising, bleeding, tiredness, or paleness .
Rhabdomyolysis: Advise patients to contact their healthcare provider if they experience severe muscle pain or weakness, or if they experience reddish-brown urine .
Hepatotoxicity: Advise patients to contact their healthcare provider immediately for yellowing of skin and eyes (jaundice), pain in the upper right quadrant, severe nausea or vomiting, difficulty in concentrating, disorientation, or confusion .
Cardiomyopathy: Advise patients to contact their healthcare provider immediately for new onset chest pain, shortness of breath, fatigue, lower extremity edema, or heart palpitations .
Capillary leak syndrome: Advise patients to report symptoms such as edema with or without hypotension
Extravasation: Inform patients of the risks of extravasation and to notify their healthcare provider for redness, swelling, itchiness and discomfort or leakage at the injection site . …
Warnings & precautions
Do not take this medicine if: EVDI is contraindicated in patients with known severe hypersensitivity, including anaphylaxis, to trabectedin.
Neutropenic sepsis, including fatal cases, can occur with EVDI. In Trial ET743-SAR-3007, the incidence of Grade 3 or 4 neutropenia, based on laboratory values, in patients receiving trabectedin was 43% (161/378). The median time to the first occurrence of Grade 3 or 4 neutropenia was 16 days (range: 8 days to 9.7 months); the median time to complete resolution of neutropenia was 13 days (range: 3 days to 2.3 months). Febrile neutropenia (fever ≥38.5°C with Grade 3 or 4 neutropenia) occurred in 18 patients (5%) treated with trabectedin. Ten patients (2.6%) experienced neutropenic sepsis, 5 of whom had febrile neutropenia, which was fatal in 4 patients (1.1%).
Assess neutrophil count prior to administration of each dose of EVDI and periodically throughout the treatment cycle. Withhold or reduce dose of EVDI based on severity of adverse reaction .
EVDI can cause rhabdomyolysis and musculoskeletal toxicity. In Trial ET743-SAR-3007, rhabdomyolysis leading to death occurred in 3 (0.8%) of the 378 patients receiving trabectedin. Elevations in creatine phosphokinase (CPK) occurred in 122 (32%) of the 378 patients receiving trabectedin, including Grade 3 or 4 CPK elevation in 24 patients (6%), compared to 15 (9%) of the 172 patients receiving dacarbazine with any CPK elevation, including 1 patient (0.6%) with Grade 3 CPK elevation. Among the 24 patients receiving trabectedin with Grade 3 or 4 CPK elevation, renal failure occurred in 11 patients (2.9%); rhabdomyolysis with the complication of renal failure occurred in 4 of these 11 patients (1.1%). The median time to first occurrence of Grade 3 or 4 CPK elevations was 2 months (range: 1 to 11.5 months). The median time to complete resolution was 14 days (range: 5 days to 1 month). …
Trabectedin side effects
The following adverse reactions are discussed in more detail in other sections of the labeling:
Anaphylaxis
Neutropenic Sepsis
Rhabdomyolysis
Hepatotoxicity
Cardiomyopathy
Capillary Leak Syndrome
Extravasation Resulting in Tissue Necrosis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to trabectedin in 755 patients with soft tissue sarcoma including 197 (26%) patients exposed to trabectedin for greater than or equal to 6 months and 57 (8%) patients exposed to trabectedin for greater than or equal to 1 year. The safety of trabectedin was evaluated in six open-label, single-arm trials, in which 377 patients received trabectedin and one open-label, randomized, active-controlled clinical trial in which 378 patients received trabectedin (Trial ET743-SAR-3007). All patients received trabectedin at the recommended dosing regimen of 1.5 mg/m2 administered as an intravenous infusion over 24 hours once every 3 weeks (q3wk, 24-h). The median age was 54 years (range: 18 to 81 years), 63% were female, and all patients had metastatic soft tissue sarcoma. …
Drug interactions
Table 5 describes drug interactions where concomitant use of another drug affects EVDI.
Table 5: Drug Interactions with EVDI
Strong CYP3A Inhibitors
Prevention or Management | Avoid concomitant use of strong CYP3A inhibitors in patients taking EVDI. If concomitant use of a strong CYP3A inhibitor for short-term use (i.e., less than 14 days) cannot be avoided, administer the strong CYP3A inhibitor 1 week after the EVDI infusion, and discontinue it the day prior to the next EVDI infusion
Mechanism and Clinical Effect(s) | Concomitant administration of trabectedin with ketoconazole, a strong CYP3A inhibitor, increased systemic exposure of trabectedin by 66% .
Strong CYP3A Inducers
Prevention or Management | Avoid concomitant use of strong CYP3A inducers in patients taking EVDI.
Mechanism and Clinical Effect(s) | Concomitant administration of trabectedin with rifampin, a strong CYP3A4 inducer, decreased systemic exposure of trabectedin by 31% .
About this medicine
Trabectedin is an alkylating drug with the chemical name (1'R,6R,6aR,7R,13S,14S,16R)-5- (acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl- spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one. The molecular formula is C39H43N3O11S. The molecular weight is 761.84 g/mol.
The chemical structure is shown below:
Trabectedin is hydrophobic and has a low solubility in water.
EVDI (trabectedin) injection is supplied as a sterile clear, colorless to pale brownish-yellow solution in a single-dose vial. Each single-dose vial contains 1 mg of trabectedin in 20 mL solution (0.05 mg/mL), glycine 50 mg, lactic acid 10 mg (for pH adjustment to 3.5 to 4.2), propylene glycol 1.04 g and Water for Injection, q.s.
How it works: Trabectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c1d50f5c-4202-27f3-4798-a9708114ddea. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate